Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia

Keyphrases

• Dual Inhibitor 100%
• Dutasteride 100%
• Benign Prostatic Hyperplasia 100%
• 5α-reductase 100%
• Placebo 50%
• Prostate Volume 50%
• Risk Reduction 50%
• Symptom Score 50%
• Dihydrotestosterone 50%
• Acute Urinary Retention 50%
• Clinical Trials 25%
• Prostate-specific Antigen Level 25%
• Isoenzymes 25%
• Moderate to Severe 25%
• Total Prostate-specific Antigen 25%
• Surgical Intervention 25%
• Potent Inhibitor 25%
• Double-blind Trial 25%
• Improvement Factor 25%
• Transrectal Ultrasonography 25%
• Severe Symptoms 25%
• As(III) 25%
• Maximal Flow Rate 25%
• Index Score 25%
• American Urological Association 25%
• Multiple Interval 25%
• Peak Flow Rate 25%
• Placebo Lead-in 25%
• Interval Assessment 25%
• Transition Zone Volume 25%
• Urinary Surgery 25%
• Prostate Zones 25%

Medicine and Dentistry

• Dutasteride 100%
• Prostate Hypertrophy 100%
• Steroid 5alpha Reductase 100%
• Placebo 75%
• Risk Reduction 50%
• Androstanolone 50%
• Urinary Retention 50%
• Clinical Trial 25%
• Prostate Specific Antigen 25%
• Transrectal Ultrasonography 25%
• Peak Expiratory Flow 25%
• American Urological Association Symptom Index 25%
• Isoenzyme 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Dutasteride 100%
• Prostate Hypertrophy 100%
• Steroid 5alpha Reductase 100%
• Placebo 75%
• Androstanolone 50%
• Urine Retention 50%
• Clinical Trial 25%
• Prostate Specific Antigen 25%
• Isoenzyme 25%